

References

S-144

1. Welsch C, Rust W, Csete M. Concise review: Lessons learned from islet transplant clinical trials in developing stem cell therapies for type 1 diabetes. *Stem Cells Translational Medicine*. 2019;8(3):209-214.
2. Lablanche S, Vantyghem MC, Kessler L, et al. Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): A multicenter, randomized controlled trial. *Lancet Diabetes Endocrinol*. 2018;6(7):527-537.
3. Food and Drug Administration Center for Biologics Evaluation and Research. Cellular, Tissue and Gene Therapies Advisory Committee meeting minutes. 2021.
4. Witkowski P, Philipson LH, Kaufman DB, et al. The demise of islet allotransplantation in the United States: A call for an urgent regulatory update. *Am J Transplant*. 2021;21(4):1365-1375.
5. Zhang YJ, Duan DD, Yuan H. Efficacy and safety of islet autotransplantation after total pancreatectomy in chronic pancreatitis: A systematic review and meta-analysis including 17 studies. *Clin Res Hepatol Gastroenterol*. 2020;44(4):598-608.
6. Kempeneers MA, Scholten L, Verkade CR, et al. Efficacy of total pancreatectomy with islet autotransplantation on opioid and insulin requirement in painful chronic pancreatitis: A systematic review and meta-analysis. *Surgery*. 2019;166(3):263-270.
7. Abu-El-Haija M, Anazawa T, Beilman GJ, et al. The role of total pancreatectomy with islet autotransplantation in the treatment of chronic pancreatitis: A report from the International Consensus Guidelines in chronic pancreatitis. *Pancreatol*. 2020;20(4):762-771.
8. Morgan KA, Lancaster WP, Owczarski SM, Wang H, Borckardt J, Adams DB. Patient selection for total pancreatectomy with islet autotransplantation in the surgical management of chronic pancreatitis. *J Am Coll Surg*. 2018;226(4):446-451.
9. Lablanche S, Borot S, Wojtusciszyn A, et al. Ten-year outcomes of islet transplantation in patients with type 1 diabetes: Data from the Swiss-French GRAGIL network. *Am J Transplant*. 2021;21(11):3725-3733.
10. Markmann JF, Rickels MR, Eggerman TL, et al. Phase 3 trial of human islet-after-kidney transplantation in type 1 diabetes. *Am J Transplant*. 2021;21(4):1477-1492.

11. Abu-El-Haija M, Anazawa T, Beilman GJ, et al. The role of total pancreatectomy with islet autotransplantation in the treatment of chronic pancreatitis: A report from the International Consensus Guidelines in chronic pancreatitis. 2020;20(4):762-771.
12. Lemos JRN, Baidal DA, Ricordi C, Fuenmayor V, Alvarez A, Alejandro R. Survival after islet transplantation in subjects with type 1 diabetes: Twenty-year follow-up. *Diabetes Care*. 2021;44(4):e67-e68.
13. Parums DV. Editorial: First Regulatory Approval for Allogeneic Pancreatic Islet Beta Cell Infusion for Adult Patients with Type 1 Diabetes Mellitus. *Med Sci Monit*. 2023;29:e941918. Published 2023 Aug 1.
14. Lantidra (donislecel-jujn) [package insert]. CellTrans, Inc. Chicago, IL. 2023.
15. Luu QF, Villareal CJ, Fritschi C, Monson RS, Oberholzer J, Danielson KK. Concerns and hopes of patients with type 1 diabetes prior to islet cell transplantation: A content analysis. *J Diabetes Complications*. 2018;32(7):677-681.
16. University of Illinois at Chicago (UIC). Islet Transplantation in Type 1 Diabetic Patients Using the UIC Protocol, Phase 3. ClinicalTrials.gov identifier: NCT00679042. Updated July 27, 2022. Accessed August 29, 2023. <https://clinicaltrials.gov/study/NCT00679042>
17. University of Illinois at Chicago (UIC). Expanded Access to Donislecel for Treatment Use. ClinicalTrials.gov identifier: NCT03791567. Updates August 29, 2023. Accessed August 29, 2023. <https://clinicaltrials.gov/study/NCT03791567>